Device Ablation

Affera Mapping System

Payments companies reported to CMS as associated with Affera Mapping System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$665Kassociated payments (2023-2025)
1,627clinicians with associated payments
1company reporting

By year

2024 $17K
2025 $649K

Payments reported as associated with Affera Mapping System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Clinical Cardiac Electrophysiology $507K
Cardiovascular Disease $107K
Family $7,488
Nurse Practitioner $6,946
Internal Medicine $5,903
Physician Assistant $5,350

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Affera Mapping System

These are the largest totals companies reported as associated with Affera Mapping System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Nicholas Olson La Jolla, CA Clinical Cardiac Electrophysiology $72,108.18
Douglas Gibson La Jolla, CA Cardiovascular Disease $52,869.10
Usman Siddiqui Winter Park, FL Clinical Cardiac Electrophysiology $27,683.73
Firas El Sabbagh Fleming Island, FL Clinical Cardiac Electrophysiology $25,741.64
Sandeep Goyal Atlanta, GA Clinical Cardiac Electrophysiology $21,063.29
Arjun Gururaj Las Vegas, NV Cardiovascular Disease $20,513.77
Antonio Moretta Sarasota, FL Clinical Cardiac Electrophysiology $18,015.34
Joshua Silverstein Pittsburgh, PA Clinical Cardiac Electrophysiology $15,896.05
Dilip Mathew Sarasota, FL Clinical Cardiac Electrophysiology $11,164.39
Amin Al-Ahmad Austin, TX Clinical Cardiac Electrophysiology $10,840.41

Prescribed Affera Mapping System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.